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Abstract 
The extent to which genetic influences on cardiovascular disease risk are mediated by 
changes in DNA methylation levels has not been systematically explored. We 
developed an analytical framework that integrates genetic fine mapping and Mendelian 
randomization with epigenome-wide association studies to evaluate the causal 
relationships between methylation levels and 14 cardiovascular disease traits.  
We identified 10 genetic loci known to influence proximal DNA methylation which 
were also associated with cardiovascular traits (P < 3.83 x 10-08). Bivariate fine 
mapping identified strong evidence that the individual variants responsible for the 
observed effects on cardiovascular traits at the ADCY3 and ADIPOQ loci were 
potentially mediated through changes in DNA methylation, whereas the other loci 
require further evaluation, though we highlight that we are unable to reliably separate 
causality from horizontal pleiotropy. Causal effect estimates ranged between 0.109-
0.992 cardiovascular trait units per standard deviation change in DNA methylation and 
were replicated using results from large-scale consortia.  
Genetic variants and CpG sites identified in this study were enriched for histone mark 
peaks in relevant tissue types and gene promoter regions. Integrating our results with 
expression quantitative trait loci data we provide evidence that variation at these 
regulatory regions is likely to also influence gene expression at these loci. 
 
Word Count: 204 
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Introduction 
Approximately 88% of trait-associated variants detected using Genome Wide 
Association Studies (GWAS) reside in non-coding regions of the genome, which 
suggests that they may be influencing mechanisms which act through gene regulation1. 
Recent studies have incorporated data on genetic variants associated with gene 
expression (expression quantitative trait loci (eQTL)) into results from GWAS of 
complex traits to help identify the putative causal variant in a genomic region, as well 
as provide evidence suggesting which genes may be influenced by this variant2-5. This 
direction of inquiry can be extended to other ‘omic’ data types to gain further insights 
into the mechanistic pathway between genetic variant and causally associated trait. In 
this study, we introduce an alternative analytical framework to integrate genetic 
predictors of DNA methylation levels with complex traits to evaluate bi-directional 
causal relationships. 
DNA methylation is an epigenetic regulation mechanism which has been shown to play 
a key role in many biological processes and disease susceptibility6-8. Recent studies 
have had success in identifying genetic variants associated with DNA methylation 
(methylation quantitative trait loci (mQTL)) and report that they appear to overlap with 
eQTL at a large number of loci across the genome9; 10. This suggests that both DNA 
methylation and gene expression could reside along the causal pathway between 
genetic variation and disease, although thus far uncovering evidence of a mediated 
effect between mQTL and traits has been limited in contrast to using eQTL11-14. 
Identifying epigenetic markers for disease risk should prove valuable in understanding 
the underlying biological mechanisms for trait-associated variants 15. Indeed, the value 
of this approach was demonstrated in a recent study that applied the SMR2 method to 
uncover pleiotropic effects between methylation levels and a range of complex traits16. 
Mendelian randomization (MR) is a method by which genetic variants robustly 
associated with modifiable exposures can be used as instrumental variables to infer 
causality amongst correlated traits 17; 18. If DNA methylation resides along the causal 
pathway between genetic variant and trait, we would expect it to be correlated with our 
trait of interest. However, much like other traits analysed in epidemiological studies, 
DNA methylation is prone to confounding and reverse causation. Using an MR 
framework we can investigate whether DNA methylation has a causal relationship with 
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a phenotypic outcome, suggesting that it may reside along the causal pathway to disease 
19. Effects such as this can be referred to as ‘mediation’, as DNA methylation is 
mediating the effect from genetic variant to phenotype along the same biological 
pathway. As discussed in a recent review, MR has advantages over alternative 
approaches in mediation analysis (such as the Causal Inference Test 20), as it can detect 
the correct direction of effect in the presence of measurement error 21. It is important to 
note that all current methods are faced with the challenge of distinguishing mediation 
from horizontal pleiotropy, defined as effects where genetic variation influences 
multiple phenotypes simultaneously22 (such as DNA methylation and a complex trait) 
via independent biological pathways.  
Recent approaches to MR have shown that the robustness of causal inference is 
improved if there are many instruments because one can evaluate whether the SNP 
effects on the causal trait are proportional to the SNP effects on the consequential trait 
17; 23. We exploit this property to evaluate the causal influence of complex traits (which 
typically have many instruments) on DNA methylation (i.e. bi-directional MR24). 
Although a pitfall of evaluating the causal influence of DNA methylation on complex 
traits is that DNA methylation is typically instrumented by only a single cis-acting 
variant. Hence, an unreliable MR estimate of causality could arise due to the mQTL 
simply being in linkage disequilibrium with a variant that influences the cardiovascular 
trait through means other than the methylation level.  
In this study we have developed and implemented a method to address this issue, which 
integrates fine mapping to evaluate the likelihood of the mQTL being the same causal 
variant as the SNP influencing the cardiovascular trait. There are also methods which 
have been devised for this purpose using intermediate traits 2; 25; 26. Therefore we have 
used the joint likelihood mapping (JLIM) method27 to support findings. We have also 
undertaken functional informatics and incorporated eQTL data as this may support 
findings suggesting that DNA methylation resides on the causal pathway between 
variant and disease. However, a limitation of using single variant instruments in general 
is that it is not possible to reliably distinguish horizontal pleiotropy from mediation 28. 
Together, the causal relationships between DNA methylation and cardiovascular traits 
are delineated into four potential categories (Figure 1): 
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1. The genetic variant has an effect on the phenotype, mediated by DNA 
methylation. 
2. The genetic variant has an effect on the phenotype by alternative biological 
mechanisms, which then has a downstream effect on DNA methylation at this 
locus. 
3. The genetic variant which influences DNA methylation is simply in linkage 
disequilibrium (LD) with another variant which is influencing the associated 
trait. 
4. The genetic variant is influencing both DNA methylation and phenotype by two 
independent biological pathways (also known as horizontal pleiotropy).  
We have developed a framework to systematically navigate through these scenarios and 
have applied it to analyse 14 different cardiovascular traits. In our discovery analysis 
we used genotype and DNA methylation data from prepubertal individuals to discover 
causal pathways on early childhood phenotypes. Replication was then undertaken using 
GWAS summary statistics from large-scale consortia. 
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Materials and Methods 
The Avon Longitudinal Study of Parents and Children (ALSPAC) 
ALSPAC is a population-based cohort study investigating genetic and environmental factors 
that affect the health and development of children. The study methods are described in detail 
elsewhere 29; 30. Briefly, 14,541 pregnant women residents in the former region of Avon, UK, 
with an expected delivery date between 1st April 1991 and 31st December 1992, were eligible 
to take part in ALSPAC. Detailed information and biosamples have been collected on these 
women and their offspring at regular intervals, which are available through a searchable data 
dictionary. 
Written informed consent was obtained for all study participants. Ethical approval for the study 
was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 
Committees. 
Accessible Resource for Integrative Epigenomic Studies project (ARIES)  
Samples: Blood samples were obtained for 1,018 ALSPAC mother-offspring pairs (mothers at 
two timepoints and their offspring at three timepoints) as part of the Accessible Resource for 
Integrative Epigenomic Studies project (ARIES)31. The Illumina HumanMethylation450 
(450K) BeadChip array was used to measure DNA methylation at over 480,000 sites across 
the epigenome.  
Methylation assays: DNA samples were bisulfite treated using the Zymo EZ DNA 
MethylationTM kit (Zymo, Irvine, CA). The Illumina HumanMethylation450 BeadChip 
(HM450k) was used to measure methylation across the genome and the following arrays were 
scanned using Illumina iScan, along with an initial quality review using GenomeStudio. A 
purpose-built laboratory information management system (LIMS) was responsible for 
generating batch variables during data generation. LIMS also reported quality control (QC) 
metrics for the standard probes on the HM450k for all samples and excluded those which failed 
QC. Data points with a read count of 0 or with low signal:noise ratio (based on a p-value > 
0.01) were also excluded based on the QC report from Illumina to maintain the integrity of 
probe measurements. Methylation measurements were then compared across timepoints for the 
same individual and with SNP-chip data (HM450k probes clustered using k-means) to identify 
and remove sample mismatches. All remaining data from probes was normalised with the 
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Touleimat and Tost32 algorithms using R with the wateRmelon package33. This was followed 
by rank-normalising the data to remove outliers. Potential batch effect were removed by 
regressing data points on all covariates. These included the bisulfite-converted DNA (BCD) 
plate batch and white blood cell count which was adjusted for using the estimateCellCounts 
function in the minfi Bioconductor package34. 
Genotyping assays: Genotype data were available for all ALSPAC individuals enrolled in the 
ARIES project, which had previously undergone quality control, cleaning and imputation at 
the cohort level. ALSPAC offspring selected for this project had previously been genotyped 
using the Illumina HumanHap550 quad genome-wide SNP genotyping platform (Illumina Inc, 
San Diego, USA) by the Wellcome Trust Sanger Institute (WTSI, Cambridge, UK) and the 
Laboratory Corporation of America (LCA, Burlington, NC, USA). Samples were excluded 
based on incorrect sex assignment; abnormal heterozygosity (<0.320 or >0.345 for WTSI data; 
<0.310 or >0.330 for LCA data); high missingness (>3%); cryptic relatedness (>10% identity 
by descent) and non-European ancestry (detected by multidimensional scaling analysis). After 
QC, 500,527 SNP loci were available for the directly genotype dataset. Following QC the final 
directly genotyped dataset contained 526,688 SNP loci. 
Imputation: Imputation was performed using a joint reference panel using variants discovered 
through whole genome sequencing (WGS) in the UK10K project 35 along with known variants 
taken from the 1000 genomes reference panel. Additional functionality was developed in 
IMPUTE2 36 to use each reference panel to impute missing variants in their counterparts before 
ultimately combining them together. Following Gaunt et al (2016), prior to imputation we 
performed strict filtering using Hardy-Weinberg equilibrium P > 5×10-7 & MAF > 0.01. After 
imputation we converted the dosages to bestguess genotypes and filtered to only keep variants 
with an imputation quality score ≥ 0.8. 
 
Phenotypes: The 14 phenotypes analysed in this study are highlighted in bold. At the age 7 
ALSPAC clinic (mean age: 7.5, range: 7.1 – 8.8), height was measured to the nearest 0.1cm 
using a Harpenden stadiometer (Holtain Crosswell, Dyfed, UK) and weight was measured to 
the nearest 0.1kg using Tanita electronic scales. Body Mass Index (BMI) was calculated as 
(weight (kg))/(height (m))2. Blood Pressure was measured with a Dinamap 9301 vital monitor 
completed by trained staff using the appropriate cuff size. Two readings of both systolic and 
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diastolic blood pressure (SBP & DBP respectively) were taken when the study participants 
were at rest and the mean of each were used as a measurement in our analysis. 
Non-fasting blood samples were taken from participants who attended the age 10 clinic (mean 
age: 9.9, range: 8.9–11.5). Plasma lipid concentrations (total cholesterol (TC), triglycerides 
(TG) and high density lipoprotein cholesterol (HDL)) were measured by modification of the 
standard Lipid Research Clinics Protocol with enzymatic reagents for lipid 
determination(Myers et al., 2000). Low density lipoprotein cholesterol (LDL) concentration 
was subsequently calculated using the Friedwald equation(Warnick, 1990): 
LDLc = TC – (HDLc + TG×0.45) 
 
Very low density lipoprotein cholesterol (VLDL) concentration was calculated as: 
VLDLc = TC - (HDLc + LDLc) 
apolipoprotein A (Apo A1) and apolipoprotein b (Apo B) were measured by 
immunoturbidimetric assays (Roche UK, Welwyn Garden City, UK). Interleukin 6 (IL-6) and 
adiponectin were measured by enzyme-linked immunosorbent assay (R&D Systems, 
Abingdon, UK). High-sensitivity C-reactive protein (CRP) was measured by an automated 
particle-enhanced immunoturbidimetric assay (Roche UK, Welwyn Garden City, UK). Leptin 
was measured in-house by a linked immunosorbent assay which had been validated against 
commercial methods (Wallace et al., 2001). All assay coefficients of variation were < 5%. 
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Statistical Analysis 
We undertook an mQTL-wide association study (MWAS) to evaluate the association 
between all eligible mQTL and each trait in turn. This was decided over a conventional 
epigenome-wide association study (EWAS) (i.e. evaluating the association between 
methylation levels at CpG sites and traits) due to a larger proportion of individuals in 
ALSPAC having genotype data rather than 450K data after merging on phenotypes. 
All variants with previous evidence of genetic association with DNA methylation in 
ARIES (referred to hereafter as mQTL) were used in this analysis8, and the methods 
have been described in detail previously. Briefly, to discover mQTLs, Gaunt et al8 used 
a linear regression model adjusted for age, sex, bisulphite conversion batch, the top ten 
ancestry principal components and cell counts to evaluate the associations of 8,074,398 
imputed genetic variants against each of the 395,625 eligible methylation probes. 
Methylation probes were filtered for exclusion based on evaluations by Naeem et al 37, 
using their criteria of overlapping SNPs at CpG probes, probes which map to multiple 
locations and repeats on the 450K array. A conservative multiple testing correction was 
applied to define mQTL (P<1.0 x 10-14). This threshold was selected as it equates to a 
false positive rate of 0.2% after applying a Bonferroni correction accounting for the 
number of tests undertaken previously in ARIES. Furthermore, this strict threshold 
reduces the risk of MR analyses suffering from weak instrument bias. Full details on 
the mQTL analysis can be found in the study by Gaunt et al 8. 
The mQTL discovery study used the COJO-slct routine in GCTA to identify 
independent mQTLs, which was important to ensure variants used as instruments were 
independent for downstream MR analyses.  We excluded mQTL associated with a CpG 
site which was over 1Mb distance away (known as trans-mQTL), therefore leaving 
mQTL which were only associated with a nearby CpG site (known as cis-mQTL). This 
was to reduce the possibility of pleiotropy in our analysis as variants which associated 
with methylation at multiple CpG sites across the epigenome may be influencing 
independent biological pathways simultaneously. This left 37,812 independent mQTL 
eligible for analysis. 
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Excluding trans-effects was an important consideration in our study design as we 
anticipated that single instrument MR analyses may be necessary at a later stage when 
evaluating causal effects, which therefore restricts our ability to investigate pleiotropy 
using multiple valid instruments. mQTL were analysed in turn with each trait using 
linear regression with adjustment for age and sex. A sensitivity analysis also adjusting 
for the first 10 principal components was undertaken to evaluate whether population 
stratification was influencing our results in this analysis, although we did not anticipate 
this based on previous evaluations of population structure in the ALSPAC cohort38. 
Results were plotted using a Manhattan plot using code derived from the qqman R 
package39. Scripts to generate this plot are available at the location specified in the web 
resources section. 
Mendelian randomization analysis 
Observed associations between genotype and traits which survived a stringent multiple 
testing threshold (i.e. P < 0.05/number of tests undertaken) were then analysed using 
Mendelian randomization (MR). This analysis was undertaken to estimate the potential 
causal effect of DNA methylation on cardiovascular traits, as we anticipated observing 
evidence of association having already undertaken an MWAS. MR was undertaken 
using two stage least squares (2SLS) regression with DNA methylation as our exposure, 
phenotypic trait as our outcome and using the relevant mQTL as our instrumental 
variable. Measures of DNA methylation were initially taken from the childhood time 
point in ARIES (mean age: 7.5, standard deviation: 0.15) as this was the closest time 
point to phenotype measurements. Follow-up analyses were also undertaken using 
methylation data from the birth time point (using cord blood) and the adolescent time 
point (mean age: 17.1, standard deviation: 1.01). The R package ‘systemfit’40 was used 
to obtain causal effect estimates using 2SLS.  
We replicated observed effects by undertaking a two-sample MR analysis (2SMR)41 
using estimated effects between genetic variants and associated traits obtained from 
published studies. Moreover, a two-sample framework removes any potential bias 
encountered in the discovery analysis due to effects on both methylation and trait being 
obtained in the same sample. When observed effects for sentinel mQTL were not 
available from published studies we used variants in LD with these SNPs instead (r2 > 
0.8).  
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Figure 1 illustrates the 4 possible explanations investigated where evidence of a causal 
effect was observed using MR. Figure 2 provides an overview of our approach to 
investigate these explanations. To robustly test explanation ii) we performed the reverse 
MR analysis, evaluating whether the cardiovascular trait influenced DNA methylation 
levels at the CpG site of interest. Instruments for this analysis were identified using the 
NHGRI-EBI GWAS catalog42. Relevant GWAS for interleukin-6 were not available at 
the time of analysis and so we identified instruments based on findings from Naitza et 
al 43 (P < 5.0 x 10-08). A p-value great than 0.05 indicated that explanation ii) was 
unlikely in each instance.  
Bivariate fine mapping 
Bivariate fine mapping was undertaken using FINEMAP44 at each locus detected in the 
previous analysis. FINEMAP generates a Bayes factor for each variant at a locus which 
reflects the likelihood that it is the underlying causal variant at this region. Bivariate 
fine mapping requires all variants at a locus to be fine mapped using two different effect 
estimates 1) observed effects between SNPs and DNA methylation and 2) observed 
effects between SNPs and outcome phenotypes. As all mQTL effects were initially 
pruned to identify independent loci, we only included variants which were in high LD 
(r2 ≥ 0.8) with the sentinel SNP for each association signal before applying FINEMAP 
using the default settings. Interpretation of these results is therefore based on at least 
one underlying causal variant at each loci, as follow-up analyses are necessary to 
evaluate whether multiple causal variants may be contributing to observed effects. 
Posterior probabilities to reflect the likelihood of multiple causal variants were 
calculated using FINEMAP. 
This analysis was undertaken to evaluate explanation iii), that the mQTL analysed may 
simply be in LD with the putative causal variant for the phenotypic trait. This was 
necessary as when evaluating the relationship between DNA methylation at a CpG site 
and outcome trait there may likely only be one valid instrumental variable (i.e. the 
mQTL at this region). Bivariate fine mapping in this instance therefore evaluates 
whether the causal mQTL at a locus is likely the same causal variant for the observed 
effect on the outcome trait. However, it does not rule out the possibility of a single 
variant influencing DNA methylation and outcome trait through independent biological 
pathways (i.e. explanation iv). 
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Concordance between the top SNPs for the two sets of fine mapping analyses would 
suggest that explanation i) may be responsible for the observed effect and that DNA 
methylation resides on the causal pathway between variant and phenotypic trait. 
Bivariate fine mapping using effect estimates for both methylation and cardiovascular 
traits was advantageous in this study as we were able to obtain estimates for all SNPs 
in our data set without having to rely on summary statistics. The concordance rate was 
defined as the same variant from both analyses identified as being causal after 
accounting for chance. This was achieved by identifying the rank of the top variant 
from the methylation based analysis in the list of variants from the cardiovascular trait 
analysis and then dividing that rank by the total number of variants in the region. A 
concordance rate < 0.05 suggested that explanation iii) was unlikely. To further 
evaluate explanation iii), we also used the joint likelihood mapping (JLIM) approach27. 
Although JLIM doesn’t specify the likely causal variant at a region, it can be used to 
examine whether the underlying causal variation is responsible for observed effects on 
both methylation and cardiovascular trait in a two-sample framework. Prior 
probabilities were not integrated into these analyses using FINEMAP which allowed 
for a more direct comparison with results of the JLIM method. 
Impact of mQTL on gene expression and histone modification 
We applied 2SMR to evaluate the relationship between methylation and expression 
using observed effects between SNPs and expression in relevant tissue types from the 
GTEx consortium45. When observed effects for sentinel mQTL were not available from 
GTEx we identified a surrogate SNP instead (r2 > 0.8). 
We also assessed whether any mQTL were in LD (r2 > 0.8) with any previously reported 
histone quantitative trait loci (hQTL)46. When this was true, we applied 2SMR to 
evaluate the causal relationship between methylation and histone modification at these 
loci. This analysis was for exploratory purposes as there are aspects of the relationship 
between DNA methylation and histone modification which remain unexplored, despite 
progress by recent studies47; 48. 
Functional informatics 
The variant effect predictor (VEP)49 was applied to the top ranked mQTL from the 
bivariate fine mapping analysis to calculate their predicted consequence. Enhancer 
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annotations were obtained from the 450K annotation file from Illumina and additional 
regulatory data was obtained from Ensembl50 to evaluate whether mQTL and CpG sites 
were located within regulatory regions of the genome. As we were interested in 
cardiovascular and lipid traits in this study, tissue specific data from the Roadmap 
Epigenomics Project51 was used to infer whether the potential causal variants and CpG 
sites at each locus resided within histone mark peaks and regions of DNAse 
hypersensitivity. These tissues were adipose derived mesenchymal stem cells, adipose 
nuclei, aorta, fetal heart, left ventricle, right atrium and right ventricle, which were 
selected due to their biological relevance in cardiovascular aetiology. 
Enrichment analysis was undertaken to test whether lead SNPs and associated CpG 
sites were located in regulatory regions more than can be accounted for by chance. To 
calibrate background expectations, we obtained matched SNPs using snpSNAP52 and 
identified matched CpG sites by randomly sampling probes from the 450K array which 
were in similar regions across the genome (i.e. within CpG islands/1st Exons etc.).  
Enrichment was investigated using the hypergeometric test and multiple testing was 
accounted for by randomly sampling controls SNPs/probes and re-running analyses for 
10,000 iterations. 
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Results 
Mining for putative causal influences of methylation on cardiovascular traits 
We undertook 529,368 tests to evaluate the association between previously identified 
mQTL in ARIES with each trait in turn (37,812 unique variants x 14 traits). We 
identified 10 independent association signals which, after multiple testing correction, 
provided strong evidence of association (P < 9.45 x 10-08 (i.e. 0.05/529,368)) and can 
be found in Table 1. Two of these effects were observed at the same CpG site near 
ADIPOQ, although they were identified using two independent mQTL (r2 = 0.02).  
The 10 sentinel mQTL identified in this analysis were only strongly associated with 
DNA methylation at a proximal CpG site and not any other CpG sites in the epigenome 
based on our findings in ARIES. A summary of these mQTL can be found in Table S1. 
We repeated our analysis with adjustment for the first 10 principal components, 
although results did not suggest that population stratification was an issue in this 
analysis (Table S2).  
Inferring putative causal relationships 
Putative causal effect estimates between methylation and cardiovascular traits were 
obtained at each locus in the MR analysis using mQTL as our instrumental variables 
(Table 2). Effect estimates suggested a direct relationship between methylation and 
cardiovascular traits at the IL6R [MIM: 147880], APOB [MIM: 107730], SORT1 
[MIM: 602458] and ADCY3 [MIM: 600291] loci (i.e. increased methylation results in 
an observed increase in the cardiovascular trait), whereas an inverse relationship was 
observed at the ADIPOQ [MIM: 612556], ABO [MIM: 110300], LEPR [MIM: 
601007], APOA1 [MIM: 107680] and FADS1 [MIM: 606148] loci (i.e. increased 
methylation causes a decrease in cardiovascular trait levels). Due to the two 
independent mQTL contributing to methylation at the ADIPOQ, we undertook 
multivariate MR which provided strong evidence of an inverse relationship between 
methylation and adiponectin at this locus (beta = -0.548, standard error = 0.107, P = 
3.79 x 10-7).  
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Taking these putative associations forward, we evaluated the potential for reverse 
causal relationships by performing MR of the cardiovascular traits against the DNA 
methylation levels using SNPs from GWAS as our instruments. There was no evidence 
to suggest that the putative associations were due to the cardiovascular traits influencing 
the methylation levels (Tables S3) and therefore suggests that these effects are unlikely 
to be attributed to explanation ii). 
Using methylation data from 2 other time points across the life course (at birth and 
adolescence (mean age: 17.1)) we observed consistent directions of effect as was 
observed using data from the childhood time point (mean age: 7.5) (Tables S4 & S5). 
Evidence of association was observed at each locus in this analysis except for the ABO 
and IL6R loci when using the cord data. We reproduced similar effects for 9 of the 10 
mQTLs on cardiovascular traits using effect estimates from published studies (Table 
3). The only locus we were not able to find a replication effect estimate for was the 
mQTL at IL6R as it was not in LD (r2 > 0.8) with any previously published findings for 
interleukin 6.  
Evaluating putative causal variants to infer mediated effects 
There was concordance amongst the top SNPs in the bivariate fine mapping analyses 
at the ABO, ADCY3 and ADIPOQ (common signal) loci, as the variant with the largest 
Bayes factor was the same for the effect on DNA methylation and outcome trait (Tables 
S6). These results lend support to the hypothesis that DNA methylation resides on the 
causal pathway between genetic variant and outcome trait (i.e. explanation i). There 
was a lack of concordance for the results at the ADIPOQ (low frequency signal), 
SORT1, FADS1 and LEPR loci, suggesting that the mQTL may be in LD with the 
putative causal variant for the phenotypic trait (i.e. explanation iii). Results of the JLIM 
method supported evidence at the ADIPOQ & ADCY3 loci, although we were unable 
to further evaluate signals at the ABO & IL6R regions due to unavailable GWAS 
summary results for interleukin-6 (Table S7). Posterior probabilities from FINEMAP 
suggested that there was likely only a single variant influencing trait variation for each 
observed effect (Table S7).  
Investigating the role of DNA methylation with gene expression and histone 
modification 
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To further dissect the relationship between DNA methylation and complex traits we 
sought to evaluate the influence of the methylation levels on local gene expression. We 
observed evidence of a causal relationship between methylation and expression at 8 of 
the 10 loci using data from the GTEx consortium (Table 4). Effect estimates suggest an 
inverse relationship (i.e. increased methylation results in decreased gene expression) at 
the ADIPOQ (low frequency signal) and APOA1 loci, whereas a direct relationship was 
observed at the other 6 loci (i.e. increased methylation results in increased gene 
expression). We were unable to identify a surrogate variant (r2 > 0.8) to obtain a suitable 
effect estimate at the LEPR and ADIPOQ (common signal) loci. 
mQTL at the APOA1 and IL6R loci were also in high LD with previously reported 
histone quantitative trait loci (hQTL) based on findings by Grubert et al46. Results from 
our 2SMR analyses to evaluate the influence of methylation levels on histone 
modification provided strong evidence of a causal effect as well as an inverse 
relationship in each instance (Table S8). 
Functional informatics 
To better understand the functional role underlying these putative causal associations, 
variants and CpG sites were evaluated to discern whether they reside within regulatory 
regions across the genome. An overview of the regulatory data used can be found in 
Table S9. The lead variants based on the bivariate fine mapping analysis (using effect 
estimates on DNA methylation) were used in this analysis and the VEP was used to 
predict their functional consequences (Table S10). 
Every associated CpG site identified in this study resides within multiple histone mark 
peaks based on tissue data from the Roadmap Epigenomics Project (Table S11). All 
sites also reside in either enhancer or promoter/promoter flanking regions with the 
exception of the CpG site near ADIPOQ. There was strong evidence of enrichment for 
regulatory annotations for both SNPs and CpG sites which supports previous evidence 
that they are likely to have a causal downstream effect on phenotypic variation (Table 
S12). 
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Discussion 
We have designed a framework to evaluate the putative causal influences of DNA methylation 
on complex traits and disease using Mendelian randomization. For observed effects on 
cardiovascular traits that appear to be caused by methylation, we used bivariate fine mapping 
and joint likelihood mapping to evaluate if the putative causal variant influencing methylation 
was the same causal variant responsible for influencing the trait. The bivariate fine mapping 
suggested that cardiovascular traits may be influenced by altered DNA methylation levels at 
the ABO, ADCY3, ADIPOQ, APOA1, APOB and IL6R gene regions. However, joint likelihood 
mapping only supported findings at the ADCY3 and ADIPOQ loci. This provides compelling 
evidence DNA methylation may play a mediatory role for the effects at these loci, whereas the 
remaining candidate loci require further evaluation. Furthermore, two sample MR analyses 
provided evidence that DNA methylation levels influenced gene expression at these loci, 
suggesting that predicted functional effects for the causal variants indicate a coordinated 
system of effects that are consistent with causality. This was important to demonstrate, as single 
valid instruments meant that we were unable to robustly show that variants were not 
influencing methylation and traits independently. This is a current limitation also encountered 
by an alternative approach to evaluate the relationship between DNA methylation and complex 
traits16. This type of approach is particularly attractive for therapeutic evaluation of drug targets 
as it can provide valuable insight into the underlying mechanisms between genetic variants and 
disease. 
The ABO locus identified in this study has been associated with many different traits and 
diseases by previous studies25; 53; 54, as well as evidence implicating expression quantitative 
trait loci as putative causal SNPs for this effect 55. Here we provide evidence that DNA 
methylation may reside along the causal pathway to these observed effects (MR effect estimate: 
0.29 (Standard error=0.06) change in trait per standard deviation change in methylation). A 
deletion (rs200533593) was found to be the putative causal variant for both the observed effect 
on DNA methylation and phenotypic variation.  
The observed effect of genetic variation at ADCY3 on body mass index is a relatively recent 
finding56-58. In this study, our bivariate fine mapping analysis suggests that an intergenic variant 
(rs6737082) may be responsible for the observed signal which is mediated through DNA 
methylation at this locus (MR effect estimate: 0.11 (0.05)).  Furthermore, a variant in LD with 
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rs6737082 (rs713586, r2=0.80) has been previously reported to regulate DNA methylation at 
this location in adipose tissue7.  
There were two independent effects detected in our study near the ADIPOQ gene which were 
associated with adiponectin. The common variant signal was located upstream of ADIPOQ 
within the RFC4 gene but associated with DNA methylation levels proximal to ADIPOQ, 
which can help explain this variant’s observed effect on adiponectin (MR effect estimate: -0.36 
(0.12)). Concordance in the bivariate fine mapping analysis suggested a non-coding transcript 
variant (rs169109) was responsible. The lead SNP from the ADIPOGen consortium59 at this 
locus (rs6810075) is neither an mQTL nor in high LD with rs169109 (r2 = 0.20), suggesting 
that these two association signals are influencing adiponectin levels by alternative biological 
mechanisms. The low frequency variant signal was previously detected by the UK10K project 
35, although bivariate fine mapping results as this locus suggest that the causal mQTL was in 
linkage disequilibrium with the trait-associated variant. 
The CpG site associated with the mQTL at this locus resides between the APOA1 gene and 
APOA1-antisense (APOA1-AS), a negative transcriptional regulatory of APOA1 which has 
been shown to increase APOA1 expression both in vitro and in vivo60. The highest ranked 
mQTL based on our bivariate fine mapping using estimates with DNA methylation is in a 
promoter region upstream of APOA1, suggesting that it may be more likely influencing APOA1 
rather than APOA1-AS. There are previously reported GWAS association signals at this locus 
with lipid traits61; 62. However, given the evidence in this study of a causal effect with DNA 
methylation (MR effect estimate: -0.30 (0.08)) it is likely that these are downstream effects of 
the observed effect on Apo A1 variation. Furthermore, it is more biologically plausible this is 
the case as this gene is responsible for the protein synthesis of Apo A1.  
The signal at the IL6R locus has been previously associated with a range of traits related to 
respiratory and cardiovascular health 63-65. Our results suggest that genetic variation at IL6R 
influences DNA methylation at this region, which in turn will have a downstream effect on 
interleukin-6 and subsequently other traits and diseases (MR effect estimate: 0.47 (0.18)). 
Furthermore, this association signal was not in LD with a previously reported missense variant 
at this locus (rs2228145, r2 = 0.47 in ALSPAC) which was also supported by findings from an 
in-depth functional study of this variant 66.  
Evidence from the GTEx consortium suggests that mQTL at all eight of the loci with available 
expression data overlap with eQTL effects, which serves as an independent replication of the 
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relationships discovered through DNA methylation levels. It is biologically plausible that a 
variant’s impact of DNA methylation levels may have a downstream effect on gene expression 
along the causal pathway to disease67; 68, which may help explain these observations. Effects at 
four loci in particular appear to be biologically plausible in this regard, as the likely genes 
influenced by these variants are involved in the protein synthesis of the associated trait (i.e. 
ADIPOQ with adiponectin, APOB with Apo B, APOA-I with Apo A1 and IL6R with 
interleukin-6). Furthermore, each CpG site identified in this study resides within histone mark 
peaks in adiposity tissue according to data from the Roadmap Epigenomics project where we 
observed enrichment compared to matched CpG sites in similar regions of the genome. 
As with any study which applies MR using a single instrument to investigate causal 
relationships in epidemiology, an important limitation is the inability to disentangle potential 
pleiotropic effects where the same causal variant influences both exposure (i.e. DNA 
methylation) and outcome (i.e. cardiovascular trait) through independent pathways. To reduce 
the possibility of this we selected mQTL in our study that were only influencing proximal CpG 
sites and not elsewhere in the epigenome, as such instruments would be more likely to 
influencing traits via alternative biological mechanisms. Although in ARIES there are CpG 
sites which have 2 or 3 independent instruments (such as the CpG site at ADIPOQ in this 
study), distinguishing mediation from pleiotropy at these loci remains a challenging endeavour.  
Future studies which continue to uncover mQTL across the genome (as well as across various 
tissue types) should facilitate analyses which are able to robustly address concerns over 
pleiotropy by using methods such as MR-Egger 69. These findings should also facilitate 
analyses which model the joint effects of multiple causal mQTL at loci across the genome, as 
opposed to evaluating mQTL effects independently of each other as we have in this study. 
Weak instrumental variables and reverse causation are other factors which can bias MR 
analyses. Our analysis is unlikely to have suffered from the former as each mQTL had a large 
effect on DNA methylation in cis (P < 1.0 x 10-14) and were robustly associated with traits 
which we were able to replicate using results from studies with large population samples. We 
conducted analyses to evaluate whether reverse causation was an issue in our study (i.e. trait 
variation was causal to changes in DNA methylation at each locus), although results suggested 
that this was not the case. 
In this study we have demonstrated the value of two-sample Mendelian randomization (2SMR) 
to undertake MR analyses using summary statistics 41; 70. This allowed us to provide evidence 
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of replication for the observed effects in our study as well as investigate the relationship 
between DNA methylation and expression along the causal pathway to disease. This approach 
has the attractive advantage of enabling the potential epigenetic-complex trait interplay to be 
interrogated on a much wider scale, foregoing the requirement that ‘omic’ data and phenotypes 
are measured in the same sample. 
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Description of Supplemental Data 
Supplemental data includes Tables S1-S12. 
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Figures 
Figure 1: Explanations evaluated to explain observed associations between 
methylation quantitative trait loci and trait outcomes 
i) The genetic variant has an effect on the phenotype, mediated through DNA methylation. ii) 
The genetic variant has an effect on the phenotype by alternative biological mechanisms, which 
then has a downstream effect on DNA methylation at this locus. iii) The genetic variant which 
influences DNA methylation is simply in linkage disequilibrium with another variant which is 
influencing the associated trait. iv)  The genetic variant is influencing both DNA methylation 
and phenotype by two independent biological pathways (also known as horizontal pleiotropy).  
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Figure 2: Analysis pipeline to evaluate explanations for observed associations 
between methylation quantitative trait loci and trait outcomes 
This flowchart provides an overview of the analysis plan in this study to evaluate 4 different 
explanations which may explain trait-associated methylation quantitative trait loci (mQTL). 
LD – linkage disequilibrium, GWAS – Genome-wide association study.
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Figure 3: Manhattan plot illustrating observed association between methylation 
quantitative trait loci and cardiovascular traits 
Manhattan plot illustrating the observed association between methylation quantitative trait loci 
(mQTL) and various cardiovascular traits. Points represent –log10 p-values (y-axis) for genetic 
variants according to their genomic location (x-axis). Effects that survive the multiple testing 
threshold in our analysis (P < 9.45 x 10-08 – represented by the red horizontal line) are coloured 
according to their associated trait and annotated according to the likely impacted gene. 
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Tables 
Table 1: Results of linear regression analysis between genetic variants and traits 
SNP Gene CpG Trait Sample Size Beta SE P-value % explained 
rs266772 ADIPOQ cg05578595 Adiponectin 4248 -0.992 0.070 1.72 x 10-44 4.51% 
rs687621 ABO cg21160290 Interleukin-6 4241 -0.265 0.022 1.15 x 10-31 3.05% 
rs13375019 LEPR cg04111102 C-reactive protein 4251 -0.213 0.022 2.65 x 10-22 2.20% 
rs7549250 IL6R cg02856953 Interleukin-6 4241 -0.176 0.022 9.71 x 10-16 1.40% 
rs169109 ADIPOQ cg05578595 Adiponectin 4248 -0.167 0.022 1.44 x 10-14 1.34% 
rs541041 APOB cg25035485 Apo B 4251 -0.209 0.028 3.76 x 10-14 1.32% 
rs7528419 SORT1 cg00908766 Apo B 4251 -0.196 0.026 4.63 x 10-14 1.30% 
rs625145 APOA1 cg04087571 Apo A1 4251 0.200 0.027 9.78 x 10-14 0.94% 
rs174544 FADS1 cg19610905 Cholesterol 4250 -0.143 0.023 8.61 x 10-10 0.86% 
rs6749422 ADCY3 cg01884057 Body mass index 6076 0.109 0.018 1.28 x 10-9 0.55% 
- SNP – Single Nucleotide Polymorphism, Gene – likely implicated gene, CpG – 450K probe ID, Trait – Associated Trait, Sample Size – sample size for 
this effect, Beta – Observed effect size (units in standard deviations), SE – Standard Error of the effect size, P-value – P-value for observed effect, % 
explained – proportion of variance in trait explained by mQTL. 
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Table 2: Results of Mendelian randomization analysis between DNA methylation and traits 
SNP Gene CpG Trait Sample Size Beta SE P-value 
rs266772 ADIPOQ cg05578595 Adiponectin 646 -0.846 0.168 5.93 x 10-7 
rs687621 ABO cg21160290 Interleukin-6 646 -0.293 0.061 1.77 x 10-6 
rs13375019 LEPR cg04111102 C-reactive protein 646 -0.265 0.076 0.001 
rs7549250 IL6R cg02856953 Interleukin-6 646 0.468 0.175 0.008 
rs169109 ADIPOQ cg05578595 Adiponectin 646 -0.363 0.121 0.003 
rs541041 APOB cg25035485 Apo B 646 0.298 0.114 0.009 
rs7528419 SORT1 cg00908766 Apo B 646 0.271 0.064 2.74 x 10-5 
rs625145 APOA1 cg04087571 Apo A1 646 -0.301 0.082 2.68 x 10-4 
rs174544 FADS1 cg19610905 Cholesterol 646 -0.363 0.121 0.003 
rs6749422 ADCY3 cg01884057 Body mass index 846 0.106 0.048 0.028 
- SNP – Single Nucleotide Polymorphism, Gene – likely implicated gene, CpG – 450K probe ID, Trait – Associated Trait, Sample Size – sample size for 
this effect, Beta – Observed effect size (units in standard deviations), SE – Standard Error of the effect size, P-value – P-value for observed effect 
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Table 3: Results of replication analysis using two-sample Mendelian randomization 
SNP Gene CpG CpG effect Trait effect 2SMR effect P-value Study 
rs266772 ADIPOQ cg05578595 0.982 (0.103) -0.629 (0.143) -0.641 (0.160) 6.50 x 10-5 
UK10K Consortium (TwinsUK 
individuals only) (2015) 
rs687621 ABO cg21160290 0.912 (0.036) -0.245 (0.026) -0.269 (0.03) 9.16 x 10
-19 Naitza et al (2012) 
rs2211651* LEPR cg04111102 0.682 (0.036) -0.170 (0.022) -0.249 (0.035) 3.09 x 10-13 Reiner et al (2012) 
rs541041 APOB cg25035485 0.627 (0.053) 0.098 (0.013) 0.156 (0.025) 2.05 x 10
-10 Kettunen et al (2016 
rs169109 ADIPOQ cg05578595 0.383 (0.036) -0.052 (0.005) -0.136 (0.017) 2.58 x 10-15 Dastani et al (2013) 
rs7528419 SORT1 cg00908766 -0.980 (0.037) -0.089 (0.012) 0.091 (0.013) 9.20 x 10
-13 Kettunen et al (2016) 
rs625145 APOA1 cg04087571 -0.884 (0.044) 0.057 (0.013) -0.064 (0.015) 1.84 x 10-5 Kettunen et al (2016) 
rs174544 FADS1 cg19610905 -0.655 (0.031) 0.047 (0.004) -0.072 (0.007) 9.73 x 10-25 
Global Lipids Genetics 
Consortium (2013) 
rs6749422 ADCY3 cg01884057 0.908 (0.026) 0.068 (0.007) 0.075 (0.008) 8.05 x 10-21 Felix et al (2016) 
- * indicates surrogate variant used (r2 >0.8), SNP – Single Nucleotide Polymorphism, Gene – likely implicated gene, CpG – 450K probe ID, CpG effect 
– effect estimate of SNP on methylation, Trait effect – effect estimate of SNP on trait, 2SMR effect – effect estimates from 2-Sample MR analysis, P-
value – P-value for observed effect, Study – published study where effect estimates for traits were obtained.
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Table 4: Results of analysis investigating causal relationship between methylation and expression using two-sample Mendelian 
randomization 
SNP Gene CpG CpG effect eQTL effect eQTL P-value eQTL tissue 2SMR P-value 
rs116552240* ABO cg21160290 0.912 (0.036) 0.548 (0.069) 1.316 x 10-13 Adipose 0.601 (0.079) 3.28 x 10-14 
rs6737082 ADCY3 cg01884057 0.908 (0.026) 0.208 (0.047) 1.456 x 10-5 Adipose 0.229 (0.052) 1.13 x 10
-5 
rs266772 ADIPOQ cg05578595 0.982 (0.103) -0.339 (0.078) 1.893 x 10-5 Adipose -0.345 (0.087) 7.67 x 10-5 
rs688456 APOA1 cg04087571 -0.884 (0.044) 0.420 (0.095) 1.789 x 10-5 Heart -0.475 (0.11) 1.58 x 10-5 
rs541041 APOB cg25035485 -0.627 (0.053) -0.370 (0.066) 6.326 x 10-08 Heart 0.590 (0.116) 4.06 x 10-7 
rs646776 SORT1 cg00908766 -0.980 (0.037) -1.240 (0.105) 1.556 x 10-20 Liver 1.265 (0.117) 4.01 x 10-27 
rs174559 FADS1 cg19610905 -0.655 (0.031) -0.707 (0.089) 5.629 x 10-13 Pancreas 1.079 (0.145) 1.04 x 10-13 
rs10908837 IL6R cg02856953 -0.303 (0.039) -0.120 (0.020) 4.171 x 10
-09 Whole Blood 0.396 (0.083) 2.05 x 10-6 
* indicates surrogate variant used (r2 >0.8), SNP – Single Nucleotide Polymorphism, Gene – likely implicated gene, CpG – 450K probe ID, CpG 
effect – effect estimate of SNP on methylation, eQTL effect – effect estimate of SNP on expression based on GTEx data, eQTL P – P-value for eQTL 
from GTEx, eQTL tissue – tissue type for observed effect according to GTEx, 2SMR effect – effect estimates from 2-Sample MR analysis, P-value – 
P-value for observed 2SMR effect 
